A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG).

被引：1
|
作者：
Drappatz, J.
Raizer, J. J.
Schiff, D.
Chi, A. S.
Batchelor, T.
Snodgrass, S. M.
Quant, E. C.
Norden, A. D.
Beroukhim, R.
Grimm, S. A.
Doherty, L. M.
Ciampa, A. S.
LaFrankie, D. C.
Ruland, S.
Gerard, M.
Hammond, S.
Wen, P. Y.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[3] Univ Virginia, Med Ctr, Charlottesville, VA USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.2050
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2050
引用
收藏
页数：1
相关论文
共 50 条
  • [1] OUTCOMES IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA (HGG) TREATED WITH BEVACIZUMAB
    Ye, L.
    Hasani, A.
    Nowak, A.
    King, A.
    Long, A.
    Trevenen, M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 72 - 72
  • [2] Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma
    Smith, Katrina H.
    Lee, Eudocia Quant
    Muzikansky, Alona
    Robins, Elizabeth
    Duda, Gerstner Dan G.
    Reardon, David A.
    Nayak, Lakshmi
    Norden, Andrew David
    Doherty, Lisa M.
    Rifenburg, Jennifer
    LaFrankie, Debra C.
    Ruland, Sandra
    Pulverenti, Julee
    Stokes, Deirdre
    Lam, Priscilla
    McCluskey, Christine Sceppa
    Gaffey, Sarah C.
    Batchelor, Tracy
    Jain, Ftakesh K.
    Wen, Patrick Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] PHASE I STUDYOF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA
    Lee, Eudocia
    Smith, Katrina
    Muzikansky, Alona
    Gerstner, Elizabeth
    Kuhn, John
    Reardon, David
    Nayak, Lakshmi
    Norden, Andrew
    Rifenburg, Jennifer
    Pulverenti, Julee
    Stokes, Deirdre
    Lam, Priscilla
    Martins, Tiago
    Hempfling, Kelly
    McCluskey, Christine
    Gaffey, Sarah
    Batchelor, Tracy
    Duda, Dan
    Jain, Rakesh
    Wen, Patrick
    NEURO-ONCOLOGY, 2014, 16
  • [4] MRI AND FET PET FOR RADIOTHERAPY PLANNING IN RECURRENT HIGH-GRADE GLIOMA (HGG) IN A PROSPECTIVE PHASE I TRIAL
    Moller, Soren
    Lundemann, Michael
    af Rosenschold, Per Munck
    Costa, Junia
    Engelholm, Silke
    Law, Ian
    Poulsen, Hans Skovgaard
    Engelholm, Svend Aage
    NEURO-ONCOLOGY, 2014, 16
  • [5] A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma
    Ibrahim, Nageatte
    Buchbinder, Elizabeth I.
    Granter, Scott R.
    Rodig, Scott J.
    Giobbie-Hurder, Anita
    Becerra, Carla
    Tsiaras, Argyro
    Gjini, Evisa
    Fisher, David E.
    Hodi, F. Stephen
    CANCER MEDICINE, 2016, 5 (11): : 3041 - 3050
  • [6] BEVACIZUMAB PLUS ERLOTINIB IN RECURRENT HIGH-GRADE GLIOMA: A PHASE II TRIAL
    Sithornsumetee, Sith
    Desjardins, Annick
    Vredenburgh, James J.
    Rich, Jeremy N.
    Gururangan, Sridharan
    Janney, D. E.
    Friedman, Allan H.
    Friedman, Henry S.
    Reardon, David A.
    NEURO-ONCOLOGY, 2009, 11 (06) : 926 - 926
  • [7] Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.
    Lee, Eudocia Quant
    Muzikansky, Alona
    Gerstner, Elizabeth Robins
    Kuhn, John G.
    Reardon, David A.
    Nayak, Lakshmi
    Norden, Andrew David
    Doherty, Lisa M.
    Rifenburg, Jennifer
    LaFrankie, Debra C.
    Pulverenti, Julee
    Vardam-Kaur, Trupti
    Stokes, Deirdre
    Smith, Katrina Howard
    McCluskey, Christine Sceppa
    Gaffey, Sarah C.
    Batchelor, Tracy
    Duda, Dan G.
    Jain, Rakesh K.
    Wen, Patrick Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma
    J. Drappatz
    E. Q. Lee
    S. Hammond
    S. A. Grimm
    A. D. Norden
    R. Beroukhim
    M. Gerard
    D. Schiff
    A. S. Chi
    T. T. Batchelor
    L. M. Doherty
    A. S. Ciampa
    D. C. LaFrankie
    S. Ruland
    S. M. Snodgrass
    J. J. Raizer
    P. Y. Wen
    Journal of Neuro-Oncology, 2012, 107 : 133 - 138
  • [9] Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma
    Drappatz, J.
    Lee, E. Q.
    Hammond, S.
    Grimm, S. A.
    Norden, A. D.
    Beroukhim, R.
    Gerard, M.
    Schiff, D.
    Chi, A. S.
    Batchelor, T. T.
    Doherty, L. M.
    Ciampa, A. S.
    LaFrankie, D. C.
    Ruland, S.
    Snodgrass, S. M.
    Raizer, J. J.
    Wen, P. Y.
    JOURNAL OF NEURO-ONCOLOGY, 2012, 107 (01) : 133 - 138
  • [10] Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma
    Lee, Eudocia Q.
    Duda, Dan G.
    Muzikansky, Alona
    Gerstner, Elizabeth R.
    Kuhn, John G.
    Reardon, David A.
    Nayak, Lakshmi
    Norden, Andrew D.
    Doherty, Lisa
    LaFrankie, Debra
    Stefanik, Jennifer
    Vardam, Trupti
    Smith, Katrina H.
    McCluskey, Christine
    Gaffey, Sarah
    Batchelor, Tracy T.
    Jain, Rakesh K.
    Wen, Patrick Y.
    CLINICAL CANCER RESEARCH, 2018, 24 (19) : 4643 - 4649
12345